Breadcrumb

Mark Roschewski, M.D.

Mark Roschewski, M.D.

  • Center for Cancer Research
  • National Cancer Institute
Lymphoid Malignancies Branch

RESEARCH SUMMARY

Dr. Roschewski is a Senior Clinician and the Clinical Director of the Lymphoid Malignancies Branch (LYMB) of the Center for Cancer Research. His research team focuses on the management of aggressive B-cell lymphomas including diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), mantle cell lymphoma (MCL), and primary CNS lymphomas (PCNSL). Recent studies from NCI show that dose-adjusted EPOCH-R is highly effective for adults with BL and specific subtypes of DLBCL, such as primary mediastinal B-cell lymphoma. The LYMB research team also recently demonstrated that targeted agents such as ibrutinib are highly effective when combined with chemotherapy in relapsed and refractory PCNSL. Dr. Roschewski has pioneered an active translational program focused on studying clonal evolution in follicular lymphoma (FL) with an aim of identifying the molecular biology of FL patients who are failed by current therapy. The FL translational program has multiple studies for FL patients who do not yet require therapy as well as multiple treatment studies for patients in need of frontline or relapsed therapy. An important research focus of the LYMB research team involves developing  non-invasive methods of monitoring disease in patients with lymphoma, including circulating tumor DNA. The LYMB research team also is dedicated to developing novel therapies for patients with rare lymphoma subtypes including EBV-associated lymphomas and lymphomas that secondarily involve the CNS.

Areas of Expertise

Burkitt Lymphoma
Diffuse Large B-Cell Lymphoma
CNS Lymphomas
Clinical Applications of Circulating Tumor DNA (ctDNA) in Lymphoma

Information for Patients

Learn more about our clinical trials and the highly specialized care teams that lead them. 

Publications

Selected Publications

Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma

Roschewski M, Dunleavy K, Abramson JS, Powell BL, Link BK, Patel P, Bierman PJ, Jagadeesh D, Mitsuyasu RT, Peace D, Watson PR, Hanna WT, Melani C, Lucas AN, Steinberg SM, Pittaluga S, Jaffe ES, Friedberg JW, Kahl BS, Little RF, Bartlett NL, Fanale MA, Noy A, Wilson WH.
J Clin Oncol. JCO2000303, 2020. [ Journal Article ]

Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study

Roschewski, M., Dunleavy, K., Pittaluga, S., Moorhead, M., Pepin, F., Kong, K., Shovlin, M., Jaffe, E. S., Staudt, L. M., Lai, C., Steinberg, S. M., Chen, C. C., Zheng, J., Willis, T. D., Faham, M., Wilson, W. H.
Lancet Oncology. 16(5): 541-9, 2015.
Full-Text Article
[ Journal Article ]

Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma

Lionakis, M. S., Dunleavy, K., Roschewski, M., Widemann, B. C., Butman, J. A., Schmitz, R., Yang, Y., Cole, D. E., Melani, C., Higham, C. S., Desai, J. V., Ceribelli, M., Chen, L., Thomas,C. J., Little, R. F., Gea-Banacloche, J., Bhaumik, S., Stetler-Stevenson, M., Pittaluga, S., Jaffe, E. S., Heiss, J., Lucas, N., Steinberg, S. M., Staudt, L. M., Wilson, W. H.
Cancer Cell. 31(6): 833-843, 2017. [ Journal Article ]

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma

Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP, Tran T, Lynn J, Chen JY, Volkmer JP, Agoram B, Huang J, Majeti R, Weissman IL, Takimoto CH, Chao MP, Smith SM.
New Engl J Med. 379(18): 1711-21, 2018. [ Journal Article ]

Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study

Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, Parekh S, Lacasce A, Hayslip JW, Jagadeesh D, Nagpal S, Lechowicz MJ, Gaur R, Lucas A, Melani C, Roschewski M, Steinberg SM, Jaffe ES, Kahl B, Friedberg JW, Little RF, Bartlett NL, Wilson WH.
Lancet Haematol. 5(12): e609-e617, 2018. [ Journal Article ]

Job Vacancies

We have no open positions in our group at this time, please check back later.

To see all available positions at CCR, take a look at our Careers page. You can also subscribe to receive CCR's latest job and training opportunities in your inbox.

Team

Staff Scientist
James D. Phelan, Ph.D.
Nurse Practitioner
Amynah Pradhan, CRNP-F, MSN, RN
Research Nurse
Anna Marie Juanitez, RN
Research Nurse
Sarah Evans, RN